RVTY

REVVITY, INC.
2 filings tracked
healthcarebiotechnologyLARGE ($10B-200B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Revvity is demonstrating strong operational momentum, reporting a 7% increase in total revenue to $711.1 million for the first quarter of fiscal year 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite top-line growth, Revvity's profitability is showing signs of strain. Gross margins contracted 200 basis points to 54.5%, weighed down by a $6 million net tariff hit and unfavorable product mix shifts.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every RVTY filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 FY26 filing reveals a company in a transition phase, balancing aggressive growth and capital returns against mounting margin pressures and debt obligations. Revvity has successfully grown its revenue and expanded its software footprint, but these gains are being offset by a 200-basis-point drop in gross margins and rising R&D costs. The tension between the 'fortress' balance sheet narrative and the reality of dwindling cash reserves suggests a tightening window for execution. Investors are now faced with a trade-off between the upside of a potential regulatory windfall and the downside of a looming debt wall in mid-2026. While the share buybacks provide a floor for the stock price, the long-term thesis depends on whether the ACD/Labs integration and AI initiatives can reverse the current margin compression. The upcoming July 2026 debt maturity will be the definitive test of Revvity's financial agility and liquidity management.

Selected Quarter

Core Takeaway

Revvity is successfully growing its revenue and software capabilities, but a looming $575M debt maturity and falling margins create a precarious financial balancing act.

Investor Lens

The trade-off between immediate shareholder returns (buybacks) and the long-term necessity of debt refinancing and margin recovery.

Watch Next

The repayment or refinancing of the 1.875% Senior Unsecured Notes due in July 2026.

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.02Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 12

Total revenue increased 7% to $711.1 million, driven by growth in both reportable segments.

earnings beat
70%
bearishMay 12

Gross margins fell 200 basis points to 54.5% due to tariffs and product mix shifts.

margin compression
80%
bullishMay 12

Active share repurchase program with $800.5 million remaining available.

buyback
60%
bearishMay 12

Significant debt maturity of $575.8 million due in July 2026.

debt restructure
90%
bullishMay 12

Acquisition of ACD/Labs to expand software and informatics capabilities.

acquisition
50%
bullishMay 12

Total revenue increased 7% to $711.1 million, driven by growth in both reportable segments.

earnings beat
70%
bearishMay 12

Gross margins fell 200 basis points to 54.5% due to tariffs and product mix shifts.

margin compression
80%
bullishMay 12

Active share repurchase program with $800.5 million remaining available.

buyback
60%
bearishMay 12

Significant debt maturity of $575.8 million due in July 2026.

debt restructure
90%
bullishMay 12

Acquisition of ACD/Labs to expand software and informatics capabilities.

acquisition
50%

Filing History

10-QMay 12, 2026
Expand Sequence

The Q1 FY26 filing reveals a company in a transition phase, balancing aggressive growth and capital returns against mounting margin pressures and debt obligations. Revvity has successfully grown its revenue and expanded its software footprint, but these gains are being offset by a 200-basis-point drop in gross margins and rising R&D costs. The tension between the 'fortress' balance sheet narrative and the reality of dwindling cash reserves suggests a tightening window for execution. Investors are now faced with a trade-off between the upside of a potential regulatory windfall and the downside of a looming debt wall in mid-2026. While the share buybacks provide a floor for the stock price, the long-term thesis depends on whether the ACD/Labs integration and AI initiatives can reverse the current margin compression. The upcoming July 2026 debt maturity will be the definitive test of Revvity's financial agility and liquidity management.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.